Last updated on December 2019

Phase 2 Randomized Open-Label Crossover PD/PK Study of a Novel Pram-Insulin Co-Formulation in Adults With T1D


Brief description of study

This is a randomized, open-label, active-controlled, single-dose, 3-treatment, 3-period, 3-way crossover, comparative PD and PK inpatient study in adults with T1D. The study comprises 5 visits: Screening (Visit 1), Treatment Periods (Visits 2 4), and Follow-Up (Visit 5).

Clinical Study Identifier: NCT04074317

Find a site near you

Start Over

World Wide Clinical Trials

San Antonio, TX United States
  Connect »